In a recent decision of the Federal Court, Amgen Inc v Pfizer Canada Inc, 2018 FC
1078, 2018 FC 1078, Prothonotary Milczynski dismissed
Pfizer's motion for summary dismissal of the proceedings under
section 6.08 of the recently amended PM(NOC) Regulations.
Prothonotary Milczynski's decision is only the second such
ruling under section 6.08, and the previous motion, which relates
to a "skinny label" submission, was also
dismissed.1
Background of the Proceeding
Pfizer, acting here as a second person, sought to market a
biosimilar product to Amgen's Neupogen and Neulasta products,
containing filgrastim and pelfilgrastim respectively. In doing so,
Pfizer served a Notice of Allegation regarding Amgen's
1,341,537 patent (the "537 Patent"), listed on the Patent
Register for both products. As this action is under the
Amended Regulations, Amgen brought its claim for
infringement of the patent, and Pfizer counterclaimed for
invalidity.